TACSTD2 and breast carcinoma: At the 2020 San Antonio Breast Cancer Conference, in a presented biomarker analysis, it was shown that the benefit in favor of sacituzumab govitecan was maintained independently of the degree of Trop-2 expression, even if the smallest progression free survival (PFS) and overall survival (OS) difference was observed in patients with low levels of Trop-2 expression in the tumor (PFS: Trop-2 high 6.9 vs. 2.5 months, Trop-2 medium 5.6 vs. 2.2 months, Trop-2 low 2.7 vs. 1.6 months; OS: Trop-2 high 14.2 vs. 6.9 months, Trop-2 medium 14.9 vs. 6.9 months, Trop-2 low 9.3 vs. 7.6 months) [32].